Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood clues may unlock fibromyalgia and muscle loss mystery

NCT ID NCT07381348

Knowledge-focused Sponsor: Ankara City Hospital Bilkent Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at blood samples from 66 women to find differences in small molecules (metabolites) between those with fibromyalgia, those with both fibromyalgia and possible sarcopenia (muscle loss), and healthy women. The goal was to identify potential biomarkers that could help diagnose or understand these conditions better. No treatments were tested; this was purely an observational study to gather knowledge.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could point toward new biomarkers for diagnosing fibromyalgia and sarcopenia, potentially leading to earlier detection and better treatments.
What could go wrong
This is a small, completed observational study (66 women) that only identifies differences in blood metabolites. It does not test any treatment, so any future applications are uncertain and require much more research.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

66 people

The number who actually took part.

Started

Jun 2022

Finished

May 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Forty-four female patients aged 18-60 years and 22 healthy female controls who applied to the physical therapy outpatient clinics of Ankara City Hospital FTR hospital and were diagnosed with Fibromyalgia according to the American Rheumatology Society (ACR) 2016 diagnostic criteria.

Ages

18 to 60 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Being between 18-60 years old 2. Being diagnosed with Fibromyalgia according to ACR 2016 diagnostic criteria 3. Having agreed to participate in the study 4. Healthy controls 5. Being a woman Exclusion Criteria: 1. Those who cannot take command due to cognitive dysfunction 2. Pregnancy 3. Those with severe cardiac disease, COPD, malignancy, neuromuscular disease, inflammatory rheumatic disease and organ failure 4. Those with orthopedic disorders that may cause limitation in joint range of motion and/or loss of motor muscle strength 5. Patients using systemic glucocorticoid, ACE-I / ARB, statin, sulfonylurea, allopurinol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fibromyalgia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fibromyalgia Sarcopenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Fibromyalgia Sarcopenia

Contacts and locations

Locations

  • Ankara Bilkent City Hospital Physical Treatment and Rehabilitation Hospital

    Ankara, Ankara, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.